May 2016 ARTICLE LIST >>
PharmaTutor (May- 2016)
Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 4, Issue 5)
Received On: 04/01/2016; Accepted On: 21/01/2016; Published On: 01/05/2016
AUTHORS:
Prajapati Krishna V*, Raj Hasumati A, Jain Vinit C, Prajapati Neelam S.
Department of Quality Assurance,
Shree Dhanvantary Pharmacy College, Kim, Surat
* krish1112k@gmail.com
ABSTRACT: This review article presents the pharmacology of combined Mesalazine and Rifaximin therapy especially in inflammatory bowel disease. Mesalazine is Used as in anti-inflammatory agent, Non-Steroidal. Rifaximin is used in Gastrointestinal Agents, Anti-infective agent. The use of Rifaximin in combination with Mesalazine has been proved to provide beneficial effect in inflammatory bowel disease. The mechanism of Mesalazine and Rifaximin is quite different. Mesalamine and Rifaximin are two different types of drugs offering some symptomatic relief to the IBD patients. Mesalamine treats inflammation, whereas, Rifaximin reduces bio burden. Patent for combination of both drugs were approved by WIPO. The main objective of this review article is to provide pharmacological information of combined therapy of Mesalazine and Rifaximin to researcher in development of combined dosage form of this.
How to cite this article: Prajapati KV, Raj HA, Jain VC, Prajapati NS; Pharmacology of Combined Mesalzine and Rifaximin Therapy for Inflammatory Bowel Disease; PharmaTutor; 2016; 4(5); 41-45
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Inflammatory bowel disease Wikipedia the free encyclopedia; en.wikipedia.org/wiki/Inflammatory_bowel_disease 2/11
2. Diagram available form: www.nlm.nih.gov/medlineplus/ency/imagepages/19219.htm
3. Diagram available form: www.medicinenet.com/crohns_disease_pictures_slideshow/article.htm
4. Goodman & Gilman’s, The Pharmacological basis of therapeutics; - 11th Ed, McGraw-Hill medical publishing division, 2006, 1047-1053
5. Diagram available form: pubs.rsc.org/en/content/articlelanding/2010/fo/c0fo00103a/unauth
6. Mesalazine Drug Info.(database available on internet): Drug Bank Available form: pubchem.ncbi.nlm.nih.gov/compound/5-Aminosalicylic%20Acid
7. Mesalazine Drug Info.(database available on internet): 5-Aminosalicylic acid _ CAS 89-57-6 _ Santa Cruz Biotech
8. Mesalazine Drug Info.(database available on internet):Chemical book Available from: www.chemicalbook.com/productchemicalpropertiesCB1480481_EN.htm
9. Mesalazine Drug Info.(database available on internet): Drug Bank Available form: www.drug bank.ca/drugs/DB00244
10. Mesalazine Drug Info. (Database available on internet): Wikipedia. Available from: en.wikepedia.org/wiki/mesalazine
11. Rifaximin Drug Info.(database available on internet): Drug Bank Available form: www.drug bank.ca/drugs/DB01220
12. Rifaximin Drug Info.(database available on internet): Rifaximin _ CAS 80621-81-4 _ Santa Cruz Biotech
13. Rifaximin Drug Info.(database available on internet):Chemical book Available from: chemicalbook.com/productchemicalpropertiesCB5244184_EN.htm
14. Rifaximin Drug Info. (Database available on internet): Wikipedia. Available from: en.wikepedia.org/wiki/rifaximin
15. Giovanni Brandimarte, Antonio Tursi, “Rifaximin plus mesalazine Followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease” Med Sci Monit, 2004, 10(5).70-73
16. Lupin Ltd, Harshal Jahagirdar, Umesh Badhe, Jisha Thomas, Rajesh Kulkarni, Shirishkumar Kulkarni et al. Therapeutic combinations and compositions for the treatment of gastrointestinal disorders .WO 2009047801 A1,2009
17. Tursi A., Papagrigoriadis S, “Review article: the current and Evolving treatment of colonic diverticular disease” Alimentary Pharmacology & Therapeutics.2009,30(6),532-546
18. Javier A. Herbert L. “Rifaximin: A Novel Non absorbed Rifamycin for Gastrointestinal Disorders” Clin Infect Dis. 2006, 42 (4): 541-547.
.png)
